Reproducibility of Vaginal Immobilization Balloons Overnight for Cervical Cancer Brachytherapy

Overview

Journal J Contemp Brachytherapy

Date 2021 Jun 14

PMID 34122567

Citations 1

Authors

Uma D Goyal

Paras P Mehta

Susan Samreth

John Gloss

Haiyan Cui

Denise Roe

Shona Dougherty

Affiliations

Soon will be listed here.

Abstract

Purpose: The use of vaginal immobilization balloons placed into the vagina for immobilization of tandem and ovoid (T+O) applicator during high-dose-rate (HDR) brachytherapy delivery has been used at our institution, and seems to have improved our patient comfort, decreased procedure time, and minimized applicator misplacement. We aimed to show that these balloons, while originally marketed for single-day use, are safe and maintain applicator positioning/dosimetry when left overnight for treatment delivery on sequential days.

Material And Methods: Forty-two paired computed tomography (CT) scans from thirteen patients who underwent T+O HDR treatments on sequential days with vaginal immobilization balloons overnight were retrospectively compared to calculate mean change of balloon volumes and balloon/T+O distance to bony landmarks. Dosimetric planning was retroactively performed on day 2 using CT scan of each pair, and the change in estimated radiation delivery to the bladder and rectum was compared.

Results: No statistically significant overnight changes were found in balloon volumes or anterior balloon positioning. The posterior balloon shifted -0.29 ±0.46 cm ( = 0.03) to the anterior public symphysis and 0.32 ±0.50 cm ( = 0.01) to the right femoral head. The tandem shifted 0.37 ±0.39 cm ( = 0.002) to the pubic symphysis. There was no significant difference found in radiation delivered to the bladder or rectum between the paired scans.

Conclusions: This study showed minimal change in balloon volumes, balloons/T+O positioning, or in radiation dose to bladder and rectum when the applicator remained overnight. These findings support that inflatable vaginal immobilization balloons remaining overnight for additional HDR T+O treatments on sequential days, is safe and provides stable dosimetry.

Citing Articles

Proton Arc Therapy vs Interstitial HDR Brachytherapy in Gynecologic Cancer with Parametrial/pelvic Side Wall Extension.

Yi B, Mossahebi S, Modiri A, Nichols E, Guerrero M, Lamichhane N Int J Part Ther. 2022; 9(2):31-39.

PMID: 36060416 PMC: 9415748. DOI: 10.14338/IJPT-22-00013.1.

References

Ramondetta L, Sun C, Hollier L, Jarrett L, Folloder J, Tortolero-Luna G . Advanced cervical cancer treatment in Harris County: pilot evaluation of factors that prevent optimal therapy. Gynecol Oncol. 2006; 103(2):547-53. DOI: 10.1016/j.ygyno.2006.03.054. View

Viswanathan A, Thomadsen B . American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles. Brachytherapy. 2012; 11(1):33-46. DOI: 10.1016/j.brachy.2011.07.003. View

Rai B, Patel F, Chakraborty S, Sharma S, Kapoor R, Santhosh Aprem A . Bladder-rectum spacer balloon in high-dose-rate brachytherapy in cervix carcinoma. Int J Radiat Oncol Biol Phys. 2013; 85(5):e217-22. DOI: 10.1016/j.ijrobp.2012.09.037. View

Xu-Welliver M, Lin L . Evaluation of a balloon-based vaginal packing system and patient-controlled analgesia for patients with cervical cancer undergoing high-dose-rate intracavitary brachytherapy. Pract Radiat Oncol. 2014; 3(4):263-8. DOI: 10.1016/j.prro.2012.11.004. View

Gursel S, Serarslan A, Meydan A, Okumus N, Yasayacak T . A comparison of tandem ring and tandem ovoid treatment as a curative brachytherapy component for cervical cancer. J Contemp Brachytherapy. 2020; 12(2):111-117. PMC: 7207230. DOI: 10.5114/jcb.2020.94308. View

Eng T, Patel A, Ha C . Rectal and bladder dose reduction with the addition of intravaginal balloons to vaginal packing in intracavitary brachytherapy for cervical cancer. Brachytherapy. 2016; 15(3):312-318. DOI: 10.1016/j.brachy.2016.02.008. View

Arbyn M, Weiderpass E, Bruni L, de Sanjose S, Saraiya M, Ferlay J . Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2019; 8(2):e191-e203. PMC: 7025157. DOI: 10.1016/S2214-109X(19)30482-6. View

Ramondetta L, Meyer L, Schmeler K, Daheri M, Gallegos J, Scheurer M . Avoidable tragedies: Disparities in healthcare access among medically underserved women diagnosed with cervical cancer. Gynecol Oncol. 2015; 139(3):500-5. PMC: 7418500. DOI: 10.1016/j.ygyno.2015.10.017. View

. Practice Bulletin No. 168: Cervical Cancer Screening and Prevention. Obstet Gynecol. 2016; 128(4):e111-e130. DOI: 10.1097/AOG.0000000000001708. View

10.

Guo F, Cofie L, Berenson A . Cervical Cancer Incidence in Young U.S. Females After Human Papillomavirus Vaccine Introduction. Am J Prev Med. 2018; 55(2):197-204. PMC: 6054889. DOI: 10.1016/j.amepre.2018.03.013. View

11.

Malaker K, Shukla V, DSouza H, Weatherburn H . Minimizing urinary bladder radiation dose during brachytherapy for carcinoma of the cervix using balloon inflation technique. Int J Radiat Oncol Biol Phys. 2005; 61(1):257-66. DOI: 10.1016/j.ijrobp.2004.05.004. View

12.

Viswanathan A, Beriwal S, De Los Santos J, Demanes D, Gaffney D, Hansen J . American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy. Brachytherapy. 2012; 11(1):47-52. PMC: 3489267. DOI: 10.1016/j.brachy.2011.07.002. View

13.

Montana G, Fowler W . Carcinoma of the cervix: analysis of bladder and rectal radiation dose and complications. Int J Radiat Oncol Biol Phys. 1989; 16(1):95-100. DOI: 10.1016/0360-3016(89)90015-1. View

14.

Sud S, Roth T, Jones E . Clinical analysis of speculum-based vaginal packing for high-dose-rate intracavitary tandem and ovoid brachytherapy in cervical cancer. J Contemp Brachytherapy. 2018; 10(1):32-39. PMC: 5881598. DOI: 10.5114/jcb.2018.74316. View

15.

Banerjee R, Kamrava M . Brachytherapy in the treatment of cervical cancer: a review. Int J Womens Health. 2014; 6:555-64. PMC: 4045176. DOI: 10.2147/IJWH.S46247. View

16.

Gill B, Lin J, Krivak T, Sukumvanich P, Laskey R, Ross M . National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer: the impact of new technological advancements. Int J Radiat Oncol Biol Phys. 2014; 90(5):1083-90. DOI: 10.1016/j.ijrobp.2014.07.017. View

17.

Viswanathan A, Moughan J, Small Jr W, Levenback C, Iyer R, Hymes S . The quality of cervical cancer brachytherapy implantation and the impact on local recurrence and disease-free survival in radiation therapy oncology group prospective trials 0116 and 0128. Int J Gynecol Cancer. 2011; 22(1):123-31. PMC: 3246394. DOI: 10.1097/IGC.0b013e31823ae3c9. View

18.

Spees L, Wheeler S, Varia M, Weinberger M, Baggett C, Zhou X . Evaluating the urban-rural paradox: The complicated relationship between distance and the receipt of guideline-concordant care among cervical cancer patients. Gynecol Oncol. 2018; 152(1):112-118. PMC: 6321781. DOI: 10.1016/j.ygyno.2018.11.010. View

19.

Grover S, Longo J, Einck J, Puri P, Brown D, Chino J . The Unique Issues With Brachytherapy in Low- and Middle-Income Countries. Semin Radiat Oncol. 2017; 27(2):136-142. PMC: 6661890. DOI: 10.1016/j.semradonc.2016.11.005. View

20.

Tanderup K, Eifel P, Yashar C, Potter R, Grigsby P . Curative radiation therapy for locally advanced cervical cancer: brachytherapy is NOT optional. Int J Radiat Oncol Biol Phys. 2014; 88(3):537-9. DOI: 10.1016/j.ijrobp.2013.11.011. View